Commercial antibodies and their validation [v1; ref status: indexed, http://f1000r.es/43b]
Despite an impressive growth in the business of research antibodies a general lack of trust in commercial antibodies remains in place. A variety of issues, each one potentially causing an antibody to fail, underpin the frustrations that scientists endure. Lots of money goes to waste in buying and tr...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2014-10-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | http://f1000research.com/articles/3-232/v1 |
| _version_ | 1818127377454071808 |
|---|---|
| author | JLA Voskuil |
| author_facet | JLA Voskuil |
| author_sort | JLA Voskuil |
| collection | DOAJ |
| description | Despite an impressive growth in the business of research antibodies a general lack of trust in commercial antibodies remains in place. A variety of issues, each one potentially causing an antibody to fail, underpin the frustrations that scientists endure. Lots of money goes to waste in buying and trying one failing antibody after the other without realizing all the pitfalls that come with the product: Antibodies can get inactivated, both the biological material and the assay itself can potentially be flawed, a single antibody featuring in many different catalogues can be deemed as a set of different products, and a bad choice of antibody type, wrong dilutions, and lack of proper validation can all jeopardize the intended experiments. Antibodies endorsed by scientific research papers do not always meet the scientist’s requirements either due to flawed specifications, or due to batch-to-batch variations. Antibodies can be found with Quality Control data obtained from previous batches that no longer represent the batch on sale. In addition, one cannot assume that every antibody is fit for every application. The best chance of success is to try an antibody that already was confirmed to perform correctly in the required platform. |
| first_indexed | 2024-12-11T07:16:23Z |
| format | Article |
| id | doaj.art-c17c3936b16f414ebc297c51b8ef365c |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-11T07:16:23Z |
| publishDate | 2014-10-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-c17c3936b16f414ebc297c51b8ef365c2022-12-22T01:16:13ZengF1000 Research LtdF1000Research2046-14022014-10-01310.12688/f1000research.4966.15303Commercial antibodies and their validation [v1; ref status: indexed, http://f1000r.es/43b]JLA Voskuil0Everest Biotech Ltd, Upper Heyford, OX25 5HD, UKDespite an impressive growth in the business of research antibodies a general lack of trust in commercial antibodies remains in place. A variety of issues, each one potentially causing an antibody to fail, underpin the frustrations that scientists endure. Lots of money goes to waste in buying and trying one failing antibody after the other without realizing all the pitfalls that come with the product: Antibodies can get inactivated, both the biological material and the assay itself can potentially be flawed, a single antibody featuring in many different catalogues can be deemed as a set of different products, and a bad choice of antibody type, wrong dilutions, and lack of proper validation can all jeopardize the intended experiments. Antibodies endorsed by scientific research papers do not always meet the scientist’s requirements either due to flawed specifications, or due to batch-to-batch variations. Antibodies can be found with Quality Control data obtained from previous batches that no longer represent the batch on sale. In addition, one cannot assume that every antibody is fit for every application. The best chance of success is to try an antibody that already was confirmed to perform correctly in the required platform.http://f1000research.com/articles/3-232/v1Methods for Diagnostic & Therapeutic Studies |
| spellingShingle | JLA Voskuil Commercial antibodies and their validation [v1; ref status: indexed, http://f1000r.es/43b] F1000Research Methods for Diagnostic & Therapeutic Studies |
| title | Commercial antibodies and their validation [v1; ref status: indexed, http://f1000r.es/43b] |
| title_full | Commercial antibodies and their validation [v1; ref status: indexed, http://f1000r.es/43b] |
| title_fullStr | Commercial antibodies and their validation [v1; ref status: indexed, http://f1000r.es/43b] |
| title_full_unstemmed | Commercial antibodies and their validation [v1; ref status: indexed, http://f1000r.es/43b] |
| title_short | Commercial antibodies and their validation [v1; ref status: indexed, http://f1000r.es/43b] |
| title_sort | commercial antibodies and their validation v1 ref status indexed http f1000r es 43b |
| topic | Methods for Diagnostic & Therapeutic Studies |
| url | http://f1000research.com/articles/3-232/v1 |
| work_keys_str_mv | AT jlavoskuil commercialantibodiesandtheirvalidationv1refstatusindexedhttpf1000res43b |